Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Enhertu entities : Astrazeneca plc save search
ENHERTU® Granted Priority Review in the U.S. for Patients with Metastatic HER2 Positive Solid Tumors
Published: 2024-01-29 (Crawled : 11:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.24%
H: 0.07%
C: -0.1%
enhertu her2 granted review tumors positive
ENHERTU® Demonstrated Clinically Meaningful Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
Published: 2023-10-23 (Crawled : 20:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.57%
H: 1.06%
C: 0.36%
enhertu her2 tumors trial phase 2
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2-mutant Advanced Lung Cancer in DESTINY-Lung02 Phase II Trial
Published: 2023-09-11 (Crawled : 13:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -3.31%
H: 1.02%
C: 0.97%
enhertu lung cancer tumor trial
ENHERTU® Demonstrated Strong and Durable Tumor Responses in Previously Treated HER2 Mutant Advanced Lung Cancer in DESTINY-Lung02 Phase 2 Trial
Published: 2023-09-11 (Crawled : 11:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -3.31%
H: 1.02%
C: 0.97%
enhertu lung her2 cancer tumor trial
ENHERTU® Granted Two Breakthrough Therapy Designations in U.S. for Patients Across Multiple HER2 Expressing Cancers
Published: 2023-08-31 (Crawled : 14:30) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.19%
H: 0.0%
C: -1.7%
enhertu her2 granted therapy
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2-Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase II Trial
Published: 2023-07-27 (Crawled : 12:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.42%
H: 0.55%
C: -0.86%
enhertu tumors trial
ENHERTU® Demonstrated Clinically Meaningful Progression-Free Survival and Overall Survival Across Multiple HER2 Expressing Advanced Solid Tumors in DESTINY-PanTumor02 Phase 2 Trial
Published: 2023-07-27 (Crawled : 10:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.42%
H: 0.55%
C: -0.86%
enhertu her2 tumors trial
ENHERTU® Demonstrated Clinically Meaningful and Durable Responses in Patients Across Multiple HER2 Expressing Advanced Solid Tumors
Published: 2023-06-05 (Crawled : 19:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.39%
H: 0.78%
C: 0.45%
enhertu her2 tumors
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated clinically meaningful and durable responses in patients across multiple HER2-expressing advanced solid tumors
Published: 2023-06-05 (Crawled : 17:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.39%
H: 0.78%
C: 0.45%
enhertu tumors
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Showed Clinically Meaningful and Durable Responses Across Multiple HER2-expressing Tumor Types In DESTINY-PanTumor02 Phase II Trial
Published: 2023-03-06 (Crawled : 14:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.01%
H: 0.59%
C: 0.03%
enhertu tumor trial
ENHERTU® Achieved Statistically Significant Overall Survival Reducing the Risk of Death by 36% Versus Trastuzumab Emtansine (T-DM1) in Patients with HER2 Positive Metastatic Breast Cancer in DESTINY-Breast03
Published: 2022-12-07 (Crawled : 15:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.45%
H: 0.64%
C: -0.03%
enhertu risk breast positive cancer her2- her2 metastatic breast cancer
ENHERTU® (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Breast cancer in DESTINY-Breast03
Published: 2022-12-07 (Crawled : 14:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.45%
H: 0.64%
C: -0.03%
enhertu risk breast cancer her2- her2 metastatic breast cancer
ENHERTU® Significantly Delayed Disease Progression in DESTINY-Breast02 Phase 3 Trial Versus Physician’s Choice of Treatment in Patients with HER2 Positive Metastatic Breast Cancer
Published: 2022-08-15 (Crawled : 09:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.92%
H: 0.22%
C: -0.65%
enhertu treatment disease trial positive cancer her2- her2 metastatic breast cancer
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
Published: 2022-08-12 (Crawled : 12:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.09%
H: 3.83%
C: 2.98%
enhertu lung approved therapy cancer her2- her2
ENHERTU® Approved in the U.S. as the First HER2 Directed Therapy for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Published: 2022-08-12 (Crawled : 08:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 0.09%
H: 3.83%
C: 2.98%
enhertu lung approved therapy cancer her2- her2
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer
Published: 2022-07-25 (Crawled : 12:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.43%
H: 0.39%
C: -0.04%
enhertu granted review cancer her2- her2 metastatic breast cancer
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low Metastatic Breast Cancer
Published: 2022-07-25 (Crawled : 11:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: 1.43%
H: 0.39%
C: -0.04%
enhertu granted review cancer her2- her2 metastatic breast cancer
ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US for patients with HER2-positive metastatic breast cancer treated with a prior anti-HER2-based regimen
Published: 2022-05-05 (Crawled : 12:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.35%
H: 0.4%
C: -1.2%
enhertu approved cancer breast cancer her2- her2 metastatic breast cancer
ENHERTU® Approved in the U.S. for Patients with HER2 Positive Metastatic Breast Cancer Treated with a Prior Anti-HER2-Based Regimen
Published: 2022-05-05 (Crawled : 10:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -1.35%
H: 0.4%
C: -1.2%
enhertu approved positive cancer breast cancer her2- her2 metastatic breast cancer
ENHERTU® Granted Priority Review in the U.S. for Patients with Previously Treated HER2 Mutant Metastatic Non-Small Cell Lung Cancer
Published: 2022-04-19 (Crawled : 11:00) - biospace.com/
AZN | News | $68.56 0.29% 0.29% 4.7M
|
Health Technology
|
| O: -0.44%
H: 0.66%
C: -0.42%
enhertu granted review cancer her2- her2
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.